Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02309554
Other study ID # A13-126
Secondary ID
Status Completed
Phase Phase 1
First received July 14, 2014
Last updated July 29, 2016
Start date December 2014
Est. completion date March 2016

Study information

Verified date July 2016
Source CONRAD
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review BoardDominican Republic: Consejo Nacional de Bioetica en Salud
Study type Interventional

Clinical Trial Summary

This post coital test study is a Phase I multi-center, randomized, crossover, non-significant risk device study to be carried out at two clinical sites/centers. The products to be tested are the SILCS diaphragm with 3% Nonoxynol-9 Gel (N-9) (spermicide), the SILCS diaphragm with ContraGel, and the SILCS diaphragm alone. Participants will be randomized to the order of product use, with a goal of 10 participants completing the study.


Description:

Each participant will be seen in approximately nine visits, over a period of 6-8 months, and will be contacted approximately 7 days after the final visit. Volunteers will be consented at Visit 1 and undergo procedures to confirm they are eligible to continue in the study.

Each participant will undergo four postcoital test (PCT) cycles:

1. The first PCT cycle will be a baseline cycle, done without the use of any product, in order to demonstrate the participant's ability to undergo normal ovulatory events and to produce receptive, midcycle cervical mucus. The partner's ability to produce motile sperm capable of penetrating the cervical mucus is also evaluated in this cycle.

2. Test PCT cycles will be carried out during the subsequent menstrual cycles using either the SILCS diaphragm with 3% N-9, the SILCS diaphragm with ContraGel, or the SILCS diaphragm alone following a sequence of randomized treatment. Cycles may need to be repeated depending on the characteristics of the cervical mucus and the number of sperm found in the vaginal pool and endocervical specimens.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date March 2016
Est. primary completion date March 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Age 18-45 years, inclusive

2. General good health, by volunteer history and per investigator judgment

3. History of regular menstrual cycles of 24-35 days (inclusive), by volunteer report

4. History of Pap smears and follow-up consistent with standard medical practice as outlined in the Study Manual or willing to undergo a Pap smear at Visit 1

5. Willing to abstain from intercourse and use of vaginal products as required in the protocol

6. Willing to use non-spermicidal, lubricated condoms from the first day of each menstrual cycle until 72 hours before expected midcycle

7. In a mutually monogamous relationship for at least the last four months with a male partner who: 7a. Is at least 18 years old; 7b. Has no known risk for STIs; 7c. Is willing and able to comply with protocol requirements including sexual activity/ abstinence and condom use requirements; and 7d. Can engage in vaginal intercourse with the participant, with and without condoms, as specified in protocol

8. Protected from pregnancy by female tubal sterilization

9. Vaginal and cervical anatomy that, in the opinion of the investigator, lends itself to easy genital tract sample collection

10. Willing to give voluntary consent, sign an informed consent form and comply with study procedures as required by the protocol

Exclusion Criteria:

1. History of hysterectomy

2. Vasectomy in male partner

3. Sterility or known history of sperm dysfunction in male partner

4. Currently pregnant or within two calendar months from the last pregnancy outcome. Note: If recently pregnant must have had at least two spontaneous menses since pregnancy outcome

5. Current use of any hormonal contraceptive or a copper IUD, or use of Depo-Provera in the last 120 days

6. Currently breastfeeding or having breastfed an infant in the last two months, or planning to breastfeed during the course of the study

7. Significant gynecological abnormalities (including abnormal vaginal bleeding or excessive vaginal discharge)

8. Device does not appropriately fit volunteer, as determined by clinician

9. Inability to insert, position, and/or remove study device, by clinician or volunteer

10. History of sensitivity/allergy to 3% N-9, latex, ingredients in ContraGel, or silicone, for either the volunteer or her male partner

11. In the last six months, either the volunteer or her male partner diagnosed with or treated for any STI or pelvic inflammatory disease. Note: Women with a history of genital herpes or condylomata who have been asymptomatic for at least six months may be considered for eligibility

12. Positive test for Trichomonas vaginalis, Neisseria gonorrhea or Chlamydia trachomatis

13. Deep epithelial genital findings such as abrasions, ulcerations, and lacerations, or vesicles suspicious for a sexually transmitted infection

14. Positive test for HIV

15. Chronic or acute vulvar or vaginal symptoms (pain, irritation, spotting, etc.)

16. Known current drug or alcohol abuse which could impact study compliance

17. Participation in any other investigational trial within the last 30 days or planned participation in any other investigational trial during the study

18. History of gynecological procedures (including genital piercing) on the external genitalia, vagina or cervix within the last 14 days

19. Abnormal finding on laboratory or physical examination or a social or medical condition in either the volunteer or her male partner which, in the opinion of the investigator, would make participation in the study unsafe or would complicate interpretation of data

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Other:
SILCS diaphragm used with ContraGel
SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. ContraGel is a clear, water soluble greaseless gel packed in a metal tube.
SILCS diaphragm used with 3% Nonoxynol-9
SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. 3% Nonoxynol-9 (branded as Gynol II) is clear, unscented water soluble greaseless gel packed in plastic tubes with a vaginal applicator.
SILCS diaphragm
SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring

Locations

Country Name City State
Dominican Republic ProFamilia Santo Domingo
United States Clinical Research Center, Eastern Virginia Medical School Norfolk Virginia

Sponsors (1)

Lead Sponsor Collaborator
CONRAD

Countries where clinical trial is conducted

United States,  Dominican Republic, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of women with an average of fewer than 5 progressively motile sperm per high powered field (HPF) as a measure of preliminary effectiveness Fewer than 5% progressively motile sperm per high power field is considered indicative of acceptable barrier function. Will be calculated separately for each test cycle. 2-3 hours following coitus No
Primary Per-women average number (across 9 HPFs) of progressively motile sperm per HPF as a measure of preliminary effectiveness. Mean, median, standard deviation and IQR will be assessed for the baseline cycle and during each test PCT, across all women. Qualitative assessments of change from baseline, if any, will be based on medians and IQRs. 2-3 hours following coitus No
Secondary Number of treatment emergent adverse experiences among female participants as a measure of safety Urogenital, product-related, and/or serious AEs will be assessed Beginning at Visit 2 through 7-10 days after the final study visit; an average of 6-8 months Yes
Secondary Number of treatment emergent adverse experiences among male partners as a measure of safety Urogenital, product-related, and/or serious AEs will be assessed Beginning at Visit 2 through 7-10 days after the final study visit; an average of 6-8 months Yes
See also
  Status Clinical Trial Phase
Completed NCT02577601 - Impact of Combined Hormonal Contraceptives on UPA Phase 4
Completed NCT03153644 - Improving Contraceptive Care for Women With Medical Conditions
Completed NCT04112095 - Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use Phase 3
Recruiting NCT05521646 - Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative N/A
Active, not recruiting NCT04291001 - Ovarian Function With ENG Implant and UPA Use Early Phase 1
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Completed NCT03438682 - Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
Active, not recruiting NCT01948882 - Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women N/A
Enrolling by invitation NCT04997499 - Adolescent Subcutaneous (SQ) Injection Video Validation N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03154125 - Sayana® Press Extension Study Phase 3
Withdrawn NCT03725358 - A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon. N/A
Completed NCT02957630 - "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study" Phase 1/Phase 2
Completed NCT02456584 - Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods Phase 1
Completed NCT02718222 - Impact and Performance of Institutionalizing Immediate Post-partum IUD Services N/A
Recruiting NCT02121067 - LNG-IUS at 2 Weeks Postpartum Phase 4
Terminated NCT02169869 - Immediate Postplacental IUD Insertion N/A
Recruiting NCT02292056 - Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions N/A
Withdrawn NCT01930994 - Kenya Sino-implant (II) PK Study N/A